https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38300 AntagomiRs are synthetic antagonists of miRNA, which prevent the target mRNA from suppression. Therapeutic approaches that modulate miRNAs have immense potential in the treatment of chronic respiratory disorders. However, the successful delivery of miRNAs/antagomiRs to the lungs remains a major challenge in clinical applications. A range of materials, namely, polymer nanoparticles, lipid nanocapsules and inorganic nanoparticles, has shown promising results for intracellular delivery of miRNA in chronic respiratory disorders. This review discusses the current understanding of miRNA biology, the biological roles of antagomiRs in chronic respiratory disease and the recent advances in the therapeutic utilization of antagomiRs as disease biomarkers. Furthermore our review provides a common platform to debate on the nature of antagomiRs and also addresses the viewpoint on the new generation of delivery systems that target antagomiRs in respiratory diseases.]]> Wed 27 Oct 2021 10:02:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33086 Wed 15 Dec 2021 16:08:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39066 in vitro release study, molecular simulations and was evaluated for in vitro anti-inflammatory activity. Results: Results showed that Nio-Curc had a mean particle size of 284.93 ± 14.27 nm, zeta potential of -46.93 and encapsulation efficacy of 99.62%, which demonstrates optimized physicochemical characteristics. Curcumin release in vitro could be sustained for up to 24 h. Additionally, Nio-Curc effectively reduced mRNA transcript expression of pro-inflammatory markers; IL-6, IL-8, IL-1β and TNF-a in immortalized human airway basal cell line (BCi-NS1.1). Conclusion: In this study, we have demonstrated that Nio-Curc mitigated the mRNA expression of pro-inflammatory markers in an in vitro study, which could be applied to treatment of asthma with further studies.]]> Tue 03 May 2022 12:13:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33591 Thu 22 Nov 2018 13:41:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33589 Thu 22 Nov 2018 13:41:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42345 Mon 22 Aug 2022 13:54:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42611 Fri 26 Aug 2022 14:51:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46350 Fri 18 Nov 2022 10:03:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33593 Fri 01 Apr 2022 09:22:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32345 Fri 01 Apr 2022 09:21:37 AEDT ]]>